Cencora/$COR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cencora
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices and global specialty drug logistics (World Courier). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
- Ticker
- $COR
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 49,000
- Headquarters
- Conshohocken, United States
- Website
- www.cencora.com
Cencora Metrics
BasicAdvanced
$67B
19.49
$17.95
0.57
$2.40
0.69%
Price and volume
Market cap
$67B
Beta
0.57
52-week high
$377.54
52-week low
$244.82
Average daily volume
1.3M
Dividend rate
$2.40
Financial strength
Current ratio
0.937
Quick ratio
0.5
Long term debt to equity
3.005
Total debt to equity
3.06
Dividend payout ratio (TTM)
13.69%
Interest coverage (TTM)
9.54%
Profitability
EBITDA (TTM)
5,717.409
Gross margin (TTM)
4.09%
Net profit margin (TTM)
1.03%
Operating margin (TTM)
1.38%
Effective tax rate (TTM)
23.56%
Revenue per employee (TTM)
$6,890,000
Management effectiveness
Return on assets (TTM)
3.57%
Return on equity (TTM)
129.01%
Valuation
Price to earnings (TTM)
19.492
Price to revenue (TTM)
0.2
Price to book
18.14
Price to tangible book (TTM)
-3.56
Price to free cash flow (TTM)
17.417
Free cash flow yield (TTM)
5.74%
Free cash flow per share (TTM)
20.089
Dividend yield (TTM)
0.69%
Forward dividend yield
0.69%
Growth
Revenue change (TTM)
5.00%
Earnings per share change (TTM)
125.50%
3-year revenue growth (CAGR)
8.77%
10-year revenue growth (CAGR)
8.67%
3-year earnings per share growth (CAGR)
28.15%
10-year earnings per share growth (CAGR)
11.00%
3-year dividend per share growth (CAGR)
7.35%
10-year dividend per share growth (CAGR)
5.84%
What the Analysts think about Cencora
Analyst ratings (Buy, Hold, Sell) for Cencora stock.
Analyst projections of the future price of Cencora stock.
Bulls say / Bears say
Adjusted EPS rose 12.3% in fiscal 2026, and Cencora expects another 8% to 10% increase in fiscal 2027. It also raised its quarterly dividend by 10%, signalling confidence in earnings and cash generation. (Cencora)
The planned American Oncology Network acquisition would add more than 350 oncology providers across 21 states, extending Cencora’s physician-led oncology platform. That could broaden its reach in specialty care and support future growth. (Cencora)
Cencora’s fiscal 2027 headline guidance is for adjusted operating income growth of 4% to 6% and EPS growth of 8% to 10%, below its long-term targets. The planned MWI merger and Profarma sale weigh on the reported outlook, though growth looks stronger excluding these portfolio changes. (Cencora)
Price declines on some branded drugs and lower sales to a large mail-order customer have weighed on US distribution growth. Cencora also says GLP-1 medicines carry lower gross margins, so rising sales in that category may add revenue without the same profit contribution. (Cencora)
The OneOncology deal added financing costs: quarterly net interest expense rose by $58.5 million year on year, partly because of debt used to fund the acquisition. Separately, Cencora still carries $4.2 billion of opioid-related liabilities and says losses from matters outside its accrual cannot be estimated. (Cencora, SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
Cencora Financial Performance
Revenues and expenses
Cencora Earnings Performance
Company profitability
Upcoming events
Cencora News
AllArticlesVideos
Funds containing Cencora
AllUSDEURGBP
Fund name | Fund size | $COR weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 1.68% |
iShares MSCI World Health Care Sector Advanced€CBUF | $918M | 1.68% |
JPMorgan Global Equity Premium Income£JEGP | $1.6B | 1.22% |
JPMorgan Global Equity Premium Income$JEPG | $1.6B | 1.22% |
iShares Edge MSCI World Minimum Volatility$MVOL | $2.8B | 1.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.